# Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

> **NCT03993912** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Lille** · enrollment: 294 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab SC in combination with Lenalidomide
- **DRUG:** Lenalidomide PO (25mg)
- **DRUG:** Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression

## Key facts

- **NCT ID:** NCT03993912
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2026-10-07
- **Final completion:** 2026-10-07
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993912, "Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03993912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*